Related Experiment Video
Updated: May 7, 2026
12:18
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
Current management decisions in mild cognitive impairment.
Benjamin A Bensadon1, Germaine L Odenheimer
1Donald W. Reynolds Department of Geriatric Medicine, University of Oklahoma Health Sciences Center, 1122 NE 13th Street, ORB 1200, Oklahoma City, OK 73117, USA.
Clinics in Geriatric Medicine
|October 8, 2013
Summary
Early detection of Alzheimer disease (AD) relies on identifying markers for mild cognitive impairment (MCI), a precursor to dementia. Optimal clinical management of MCI requires informed judgment due to patient heterogeneity and varied research methods.
Area of Science:
- Neurology
- Geriatrics
- Cognitive Science
Background:
- Alzheimer disease (AD) early detection efforts focus on diagnostic markers to prevent or delay progression.
- Mild cognitive impairment (MCI) is recognized as a potential precursor to dementia.
- MCI is controversially linked to an increased risk of conversion to AD.
Purpose of the Study:
- To offer considerations and recommendations for the optimal clinical management of MCI.
- To synthesize findings from meta-analyses, randomized controlled trials, and literature reviews.
- To address the challenges in managing MCI due to patient heterogeneity and inconsistent research.
Main Methods:
- Emphasis on meta-analyses.
- Inclusion of randomized controlled trials.
- Review of extant literature.
Main Results:
- Substantial heterogeneity exists within the MCI patient population.
- Research methodologies for MCI studies are often inconsistent.
- Clinical judgment is critical for effective MCI management.
Conclusions:
- Optimal clinical management of MCI necessitates careful consideration of individual patient factors.
- The heterogeneity of MCI patients and research methods complicates standardized treatment protocols.
- Informed clinical judgment is paramount for navigating MCI diagnosis and management.
More Related Videos
Related Concept Videos
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:30Cognitive Development During Adulthood
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.